

- Mazidi M, Meier T, Meles KG, Mensah G, Meretoja A, Mezgebe H, Miller T, Mirrakhimov E, Mohammed S, Moran AE, Musa KI, Narula J, Neal B, Ngalesoni F, Nguyen G, Obermeyer CM, Owolabi M, Patton G, Pedro J, Qato D, Qorbani M, Rahimi K, Rai RK, Rawaf S, Ribeiro A, Safiri S, Salomon JA, Santos I, Santric Milicevic M, Sartorius B, Schutte A, Sepanlou S, Shaikh MA, Shin MJ, Shishhebor M, Shore H, Silva DAS, Sobngwi E, Stranges S, Swaminathan S, Tabares-Seisdedos R, Tadele Atnafu N, Tesfay F, Thakur JS, Thrift A, Topor-Madry R, Truelsen T, Tyrovolas S, Ukwaja KN, Uthman O, Vasankari T, Vlassov V, Vollset SE, Wakayo T, Watkins D, Weintraub R, Werdecker A, Westerman R, Wiysonge CS, Wolfe C, Workicho A, Xu G, Yano Y, Yip P, Yonemoto N, Younis M, Yu C, Vos T, Naghavi M, Murray C. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. *J Am Coll Cardiol* 2017;**70**:1–25.
2. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filipatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlstrom U, Merkely B, Drozd J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoluneniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A, Heart Failure Association of the European Society of Cardiology. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail* 2016;**18**:613–625.
3. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. *Int J Cardiol* 2014;**171**:368–376.
4. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomicis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogon JG; American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail* 2013;**6**:606–619.
5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruitlope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;**37**:2129–2200.
6. Täubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetsch J, Rode L, Weigt H, Genschel C, Lorch U, Theek C, Levin AA, Bauersachs J, Solomon SD, Thum T. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. *Eur Heart J* 2021;**42**:178–188.
7. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. *Proc Natl Acad Sci USA* 1978;**75**:285–288.
8. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. *Cell Metab* 2018;**27**:714–739.
9. Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. *Nat Rev Drug Discov* 2019;**18**:421–446.
10. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjarn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S. LNA-mediated microRNA silencing in non-human primates. *Nature* 2008;**452**:896–899.
11. Abplanalp WT, Fischer A, John D, Zeiher AM, Gosgnach W, Darville H, Montgomery R, Pestano L, Allee G, Paty I, Fougereuse F, Dimmeler S. Efficiency and target derepression of anti-miR-92a: results of a first in human study. *Nucleic Acid Ther* 2020;doi: 10.1089/nat.2020.0871.
12. Foinquinos A, Batkai S, Genschel C, Viereck J, Rump S, Gyongyosi M, Traxler D, Riesenhuber M, Spannauer A, Lukovic D, Weber N, Zlabinger K, Hasimbegovic E, Winkler J, Fiedler J, Dangwal S, Fischer M, de la Roche J, Wojciechowski D, Kraft T, Garamvolgyi R, Neitzel S, Chatterjee S, Yin X, Bar C, Mayr M, Xiao K, Thum T. Preclinical development of a miR-132 inhibitor for heart failure treatment. *Nat Commun* 2020;**11**:633.
13. Ronnebaum SM, Patterson C. The FoxO family in cardiac function and dysfunction. *Annu Rev Physiol* 2010;**72**:81–94.
14. Ni YG, Berenji K, Wang N, Oh M, Sachan N, Dey A, Cheng J, Lu G, Morris DJ, Castrillon DH, Gerard RD, Rothermel BA, Hill JA. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. *Circulation* 2006;**114**:1159–1168.
15. Kumarswamy R, Volkman I, Beermann J, Napp LC, Jabs O, Bhayadia R, Melk A, Ucar A, Chowdhury K, Lorenzen JM, Gupta SK, Batkai S, Thum T. Vascular importance of the miR-212/132 cluster. *Eur Heart J* 2014;**35**:3224–3231.

Corrigendum

doi:10.1093/eurheartj/ehaa248

Online publish-ahead-of-print 30 June 2020

Corrigendum to: Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin [*Eur Heart J* 2020;doi:10.1093/eurheartj/ehaa190]

The authors of the above paper wish to inform readers that minor grammatical and style errors were found to be present in the originally published article version.

The title has been corrected from ‘Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin’ to ‘Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin’

The final paragraph has been corrected from the previous wording:

‘In 2020, there was a major outbreak of coronavirus infection. Unlike other coronavirus infections, which mainly cause pulmonary infections, this case of coronavirus infection was characterized by heart damage. The heart grew rapidly in a short period of time and quickly returns to normal after treatment. This type of clinical presentation has been previously reported to be rare. This case report is helpful in treating other similar patient. It is suggested that early glucocorticoid anti-inflammatory therapy and immunoglobulin therapy are of important value to this type of patient.’

It now reads:

‘Unlike other coronavirus infections, which mainly cause pulmonary infections, this case of coronavirus infection was characterized by heart damage. The cardiac chamber dimensions increased in a short period of time and quickly returned to normal after treatment. This case report is helpful in treating other similar patients. It is suggested that early glucocorticoid anti-inflammatory therapy and immunoglobulin therapy may be of important value to this type of patient.’

The paper has now been corrected online.

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com